VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vanda Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.09+0.06 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Vanda Pharmaceuticals Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Segment | $216.11M | $198.77M | $192.64M | – | – | – | – | – | – | – | 100.0% | +8.7% |
| Product Segments | – | $198.77M | $192.64M | $254.38M | – | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fanapt | $117.30M | $94.30M | $90.87M | $94.73M | $95.15M | $87.48M | $84.21M | $77.28M | $75.11M | $74.35M | 54.3% | +24.4% |
| HETLIOZ net product sales | $71.43M | $76.68M | $100.17M | $159.66M | $173.54M | $160.69M | $142.98M | $115.84M | $89.98M | $71.67M | 33.1% | -6.8% |
| PONVORY net product sales | $27.37M | $27.80M | $1.60M | $0 | $0 | – | – | – | – | – | 12.7% | -1.5% |
By region
From the segment and revenue-disaggregation notes of Vanda Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.